MedPath

Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)

Phase 3
Recruiting
Conditions
Aging
Peripheral Vascular Diseases
Walking, Difficulty
Peripheral Arterial Disease
Interventions
Behavioral: Supervised Treadmill Exercise
Behavioral: Home-Based Exercise
Dietary Supplement: Nitrate-rich beetroot Juice
Registration Number
NCT06032065
Lead Sponsor
Northwestern University
Brief Summary

Supervised exercise therapy (SET), consisting of treadmill exercise conducted three times weekly at a center while supervised by healthcare personnel, is first line therapy for people disabled by lower extremity peripheral artery disease (PAD). However, travelling three times/week to a center for SET is burdensome. Compared to SET, home-based exercise is more accessible and less burdensome. Yet, evidence-based guidelines recommend SET over home-based exercise for PAD. Walking exercise is first line therapy to improve walking distance for PAD, but it does not eliminate ischemic leg symptoms in most people with PAD. The investigators' work and that of others showed that nitrate-rich beetroot juice, which increases plasma nitrite, limb perfusion, and skeletal muscle function, significantly improved exercise tolerance and reduced non-response to exercise in people with and without PAD. The investigators will use a 2 x 2 factorial design to address two major barriers to achieving benefits from exercise therapy for PAD: First, guideline recommendations for supervised exercise therapy (SET) as first line therapy for PAD. Second, the inability of exercise therapy to eliminate PAD-related disability in most people with PAD. Participants will be randomized to one of four groups for 12 weeks: Supervised treadmill exercise + nitrate rich beetroot juice; supervised treadmill exercise + placebo, home-based walking exercise + nitrate rich beetroot juice, home-based walking exercise + placebo.

Detailed Description

Supervised exercise therapy (SET), consisting of treadmill exercise conducted three times weekly at a center while supervised by healthcare personnel, is first line therapy for people disabled by lower extremity peripheral artery disease (PAD). However, travelling three times/week to a center for SET is burdensome. As of 2018, only 1.3% of patients with Medicare and symptomatic PAD had enrolled in SET. Compared to SET, home-based exercise is more accessible and less burdensome. Yet, evidence-based guidelines recommend SET over home-based exercise for PAD. In 2021, the investigators reported that a home-based exercise intervention that incorporated behavioral methods significantly improved six-minute walk in PAD, compared to an attention control group. But no randomized trials have compared SET to a home-based exercise intervention that incorporated behavioral change methods in PAD. However, 45% of people with PAD do not meaningfully respond to exercise interventions, defined as failure to improve six-minute walk by \> 20 meters. This phenomenon occurs for both supervised and home-based exercise. The investigators' work and that of others showed that nitrate-rich beetroot juice, which increases plasma nitrite, limb perfusion, and skeletal muscle function, significantly improved exercise tolerance and reduced non-response to exercise in people with and without PAD. Therefore, the investigators will use a 2 x 2 factorial design to address two major barriers to achieving benefits from exercise therapy for PAD: First, guideline recommendations for supervised exercise therapy (SET) as first line therapy for PAD. Second, the inability of exercise therapy to eliminate PAD-related disability in most people with PAD. In this 2 x 2 factorial design, participants will be randomized to one of four groups for 12 weeks: Supervised treadmill exercise + nitrate rich beetroot juice; supervised treadmill exercise + placebo, home-based walking exercise + nitrate rich beetroot juice, home-based walking exercise + placebo.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
210
Inclusion Criteria

First, all participants will be age 50 and older. Second, all participants will have PAD. PAD will be defined as either:

  1. An ABI <= 0.90 at baseline.
  2. Vascular lab evidence of PAD (such as a toe brachial pressure less than or equal to 0.70 or an ankle brachial index less than or equal to 0.90), or angiographic evidence of PAD defined as at least 70% stenosis of an artery supplying the lower extremities.
  3. An ABI of >0.90 and <1.00 who experience a 20% or greater drop in ABI in either leg after the heel-rise test.
Exclusion Criteria
  1. Above- or below-knee amputation
  2. Limb-threatening ischemia defined as an ABI <0.40 with symptoms of rest pain
  3. Wheelchair confinement or requiring a walker to ambulate
  4. Walking is limited by a condition other than PAD
  5. Current foot ulcer on bottom of foot
  6. Unwilling to drink beetroot juice
  7. Unwilling to accept randomization into either group (home based exercise or supervised exercise)
  8. Planning to engage in new walking exercise outside of the study or unwilling to refrain from new walking exercise activity during the trial.
  9. Already exercising at a level consistent with exercise intervention.
  10. End-stage kidney disease (ESKD) associated with the need for dialysis.
  11. Planned major surgery, coronary or leg revascularization during the next six months
  12. Major surgery, coronary or leg revascularization or major cardiovascular event in the previous three months
  13. Major medical illness including lung disease requiring oxygen, Parkinson's disease, a life-threatening illness with life expectancy less than six months, or cancer requiring treatment in the previous two years. [NOTE: potential participants may still qualify if they have had treatment for an early stage cancer in the past two years and the prognosis is excellent. Participants who require oxygen only at night may still qualify.]
  14. Mini-Mental Status Examination (MMSE) score < 23 or dementia. However, if the MMSE is < 23 and the Principal Investigator evaluation determines that the lower score is related to language barriers or education level, the Principal Investigator has discretion to allow a participant with MMSE < 23 to participate, as appropriate.
  15. Allergy to beetroot juice
  16. Currently consuming beetroot juice or oral nitrate or nitrite, or a beetroot supplement, and/or unwilling to avoid these during study participation. Participants currently consuming one cup of beets daily will be asked to discontinue beet ingestion for 30 days before baseline testing and throughout the clinical trial. If the potential participant is unwilling to refrain from daily beet consumption of one cup or more, they will not be eligible for the clinical trial.
  17. Unstable angina
  18. Abnormal baseline stress test without subsequent clearance for exercise by physician
  19. Non-English speaking. The SMART PAD interventions are delivered by interventionists who do not speak non-English languages. The integrity of the clinical trial requires clear and effective communication for data collection and intervention delivery. The trial does not have staff members who are fluent in non-English languages, nor does it have the ability to translate all study materials into other languages.
  20. Participation in or completion of a clinical trial in the previous three months. [NOTE: after completing a stem cell or gene therapy intervention, participants will become eligible after the final study follow-up visit of the stem cell or gene therapy study so long as at least six months have passed since the final intervention administration. After completing a supplement or drug therapy (other than stem cell or gene therapy), participants will be eligible after the final study follow-up visit as long as at least three months have passed since the final intervention of the trial.] Participants in a study that involved up to three single doses of nitrate-rich beetroot juice administered on separate days may participate if a month has passed since their last dose of nitrate-rich beetroot juice.
  21. Visual impairment that limits walking ability.
  22. Baseline blood pressure <100/45.
  23. Participation in a supervised treadmill exercise program or cardiac rehabilitation program in previous three months.
  24. Using a mouthwash containing chlorhexidine or cetylpyridinium chloride or a mouthwash determined to be bactericidal and unwilling to discontinue.
  25. In addition to the above criteria, investigator discretion will be used to determine if the trial is unsafe or not a good fit for the potential participant.

Study & Design

Study Type
INTERVENTIONAL
Study Design
FACTORIAL
Arm && Interventions
GroupInterventionDescription
Supervised treadmill exercise + nitrate rich beetroot juiceSupervised Treadmill ExerciseThis group will be participating in Supervised Treadmill Exercise and drinking nitrate rich beetroot juice for 12 weeks.
Home-based walking exercise + nitrate rich beetroot juiceHome-Based ExerciseThis group will be participating in Home-Based Exercise and drinking nitrate rich beetroot juice for 12 weeks.
Home-based walking exercise + nitrate rich beetroot juiceNitrate-rich beetroot JuiceThis group will be participating in Home-Based Exercise and drinking nitrate rich beetroot juice for 12 weeks.
Supervised treadmill exercise + nitrate rich beetroot juiceNitrate-rich beetroot JuiceThis group will be participating in Supervised Treadmill Exercise and drinking nitrate rich beetroot juice for 12 weeks.
Supervised treadmill exercise + placeboSupervised Treadmill ExerciseThis group will be participating in Supervised Treadmill Exercise and drinking placebo beetroot juice with nitrate removed for 12 weeks.
Home-based walking exercise + placeboHome-Based ExerciseThis group will be participating in Home-Based Exercise and drinking placebo beetroot juice with nitrated removed for 12 weeks.
Primary Outcome Measures
NameTimeMethod
Six-Minute Walk DistanceMeasured at baseline and 12 week follow-up

Change in six-minute walk distance

Secondary Outcome Measures
NameTimeMethod
PROMIS Mobility Questionnaire Scoremeasured at baseline and 12 weeks

PROMIS mobility score from administered PROMIS questionnaire. Score range is from zero to infinity and a higher score means a better outcome.

Walking Impairment Questionnaire (WIQ) Distance Scoremeasured at baseline and 12 weeks

WIQ distance score - Range 0-100, 100 is best.

Step Countmeasured at baseline and 12 weeks

Step count measured over seven days with the FITBIT

20-meter Improvement in Six-Minute Walk Distancemeasured at 12 weeks

Meaningful response to exercise interventions

Six-Minute Walk DistanceMeasured at baseline and 24-week follow up

Change in six-minute walk distance

Trial Locations

Locations (3)

University of Minnesota

🇺🇸

Minneapolis, Minnesota, United States

University of Chicago

🇺🇸

Chicago, Illinois, United States

Northwestern University Feinberg School of Medicine

🇺🇸

Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath